Assay of Cefotaxime
DOI:
https://doi.org/10.51984/rxr3cz61Keywords:
Cefotaxime, HPLC assay, Drug quality, Antimicrobial resistance, British PharmacopoeiaAbstract
Editorial summary prepared for the online archive; the original print article was published without an abstract.
This study assayed the active ingredient content of two brands of cefotaxime powder for parenteral use that were in use at Algala Paediatric Hospital, Tripoli, to find out whether a substandard product could be contributing to the cefotaxime resistance reported there. The content was determined by HPLC according to the British Pharmacopoeia 2001 monograph for cefotaxime injection, after optimising the methanol concentration of the mobile phase (318 ml in 1000 ml gave a retention time of about 6 minutes, a resolution of 3.6 and a symmetry factor of 1.3).
The mean content was 105.2% (SD 1.26) for the first product and 98.8% (SD 2.02) for the second, both within the pharmacopoeial limits of 90.0–110.0% of the stated amount. The authors conclude that low potency of the products does not explain the resistance, and they recommend further study of previously used products, bioavailability and the hospital’s antibiotic policy.
Downloads
References
Certon et al. Resistant pathogens was identified as a serious major issue, Resistant, Microbial, Vectors, and the Host. Feb. 2002.
http: // www. medscape. com/ viewarticle /411450 retrieved on 5-April-2009.
USA National Intelligence Council report. The Global infectious Disease Threat and its Implications for the United States. Jan. 2000.
Steven Durand, executive summary of the Population Resource Center in February 2000 Technology (CISET) Working Group on Emerging and Re-Emerging Infectious Diseases. Washington.
Theodore Kelesidis et al. Counterfeit or substandard antimicrobial drugs: a review of the scientific evidence. Journal of Antimicrobial Chemotherapy 2007; 60(2): 214-236; http://jac.oxfordjournals.org/misc/ terms .shtml. retrieved on 30-March-2009.
Dora N. Akunyili. Counterfeit drugs and pharmacovigilance, the 10th pharmacovigilance. (The study of adverse drug reactions training course held at Uppsala monitoring centre Sweden), 2005.
Syhakhang I., et al. The quality of drug private pharmacies in lao PDR: a repeat study in 1997 and 1999. Pharm world Sci. 2004; 26:333-8.
Iruka N. Okeke, Abebayo Lamikanra and Robert Edelman. Socioeconomic and Behavioral Factors Leading to Acquired Bacterial Resistance in Developing Countries. Emerging infectious diseases. 1999; 5: (No. I).
Aburugaya O, Azwied. Third generation cephalosporin resistance to gram negative bacilli, Tripoli –Libya, 2006-2007.
British pharmacopeia. Publishing on the recommendation of medicines commission, London Her Majesty's stationary office, 2001.
Downloads
Published
Issue
Section
License
This article is published open access under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0). You may copy, redistribute, adapt and build upon it for non-commercial purposes, provided you credit the authors, cite the original publication in the Journal of Medical Sciences with its DOI, indicate any changes, and distribute any adaptations under the same licence. Copyright rests with the authors. For commercial reuse, please contact the corresponding author. Full terms: https://sebhau.edu.ly/journal/joms/copyright-licensing




















